Op-Ed: Psychedelics in Practice: What the State Programs Are Teaching Us

State-regulated psychedelic therapy programs are delivering legal, regulated access at scale in the US, offering a real-world model of care that federal FDA pathways have not yet replicated. The op-ed points to Oregon, Colorado, and New Mexico as “laboratories” for implementation. Oregon and Colorado are presented as already serving thousands of people, while New Mexico is framed as pursuing tighter medical and behavioral health integration from the start, including connections to licensed healthcare systems and future reimbursement possibilities. A central argument is that state programs generate evidence not just about whether a molecule works, but about how preparation, facilitation, and integration shape outcomes and safety in diverse, real community settings. The op-ed warns of a potential “therapy vs pharmaceutical model” tension as federal approval advances, arguing states help preserve a whole-person, therapy-centered approach rather than reducing coverage to a drug-only, disease-focused benefit.